Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

被引：0
作者：
Chao Jing
Junyun Wang
Mingyue Zhu
Zhigang Bai
Baoyi Zhao
Jun Zhang
Jie Yin
Xiaobao Yang
Zongzhi Liu
Zhongtao Zhang
Wei Deng
机构：
[1] Beijing Friendship Hospital,Department of General Surgery, Medical Oncology Group
[2] Capital Medical University,CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics
[3] Beijing Key Laboratory of Cancer Invasion and Metastasis Research & National Clinical Research Center for Digestive Diseases,Central Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital
[4] Chinese Academy of Sciences/China National Center for Bioinformation,undefined
[5] Chinese Academic of Medical Sciences and Peking Union Medical College,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Immune checkpoint inhibitors; Molecular targeted therapy; Camrelizumab; Apatinib; Advanced gastric cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2597 / 2608
页数：11
相关论文
共 108 条
[1]  
Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30
[2]  
Miller KD(2012)Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone J Clin Oncol 30 1513-1518
[3]  
Jemal A(2016)The challenge of screening for early gastric cancer in China Lancet 388 2606-1396
[4]  
Kang JH(2014)Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial Lancet Oncol 15 1389-46
[5]  
Lee SI(2008)Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 36-1235
[6]  
Lim DH(2014)Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Lancet Oncol 15 1224-214
[7]  
Zong L(2015)Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential Cell 161 205-1639
[8]  
Abe M(2015)Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 373 1627-723
[9]  
Seto Y(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-40
[10]  
Noh SH(2021)First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Lancet 398 27-133
12345678910